This compound is primarily used in cancer research and therapy development due to its ability to inhibit the interaction between p53 and MDM2 proteins. By blocking this interaction, it prevents MDM2 from degrading p53, allowing p53 to accumulate and activate its tumor-suppressing functions. This mechanism is particularly valuable in cancers where p53 is wild-type but inactivated by MDM2 overexpression. The compound is studied for its potential to induce apoptosis in cancer cells, inhibit tumor growth, and enhance the efficacy of other anticancer treatments. It is also explored in preclinical models to understand its pharmacokinetics, safety profile, and therapeutic potential in various cancer types.